2. Gene
  3. REL - REL proto-oncogene, NF-kB subunit Gene

REL - REL proto-oncogene, NF-kB subunit Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：REL 原癌基因，NF-kB 亚单位

种属: Macaca mulatta

基因 ID: 717804 | 基因类型: protein coding

关于 REL

Primary_assembly 13: 47,894,611-47,937,084 reverse strand.Mmul_10:CM014348.1

This gene has 4 transcripts (splice variants), 208 orthologues and 4 paralogues.

REL 基因产物(2)

mRNA Protein Name
XM_015112447.2 XP_014967933.1 proto-oncogene c-Rel isoform X2
XM_002799234.3 XP_002799280.1 proto-oncogene c-Rel isoform X1

REL 蛋白结构

RHD-n_c-Rel

RHD-n_c-Rel: cd07933 (7 - 178)

IPT_NFkappaB

IPT_NFkappaB: cd01177 (185 - 280)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 587 a.a.
蛋白主名 其他名称

proto-oncogene c-Rel

v-rel reticuloendotheliosis viral oncogene homolog

相关产品

Approval
生物活性分子 (1)
目录号 产品名 作用方式
纯度 是否罕见病
HY-17371A (rel)-Oxaliplatin / 否
Clinical Phase
生物活性分子 (3)
目录号 产品名 作用方式
纯度 Phase
HY-122359A rel-Levormeloxifene / Phase 3
HY-117283 rel-Aprikalim Control / Phase 2
HY-135238 (rel)-RSD 921 Agonist / Phase 2
Pre-clinical Phase
生物活性分子 (129)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-15917 DL-dithiothreitol Inhibitor 99.8% 否
HY-Y1881B Copper sulfate pentahydrate, for cell culture, 98% 98.00% 否
HY-12276 MALT1 inhibitor MI-2 Inhibitor 99.73% 否
HY-Y1881A Copper sulfate pentahydrate, 99.9% 99.90% 否
HY-124179 IT-901 Inhibitor 99.32% 否
HY-139426A (rel)-ML-SI3 98.94% 否
HY-76387 rel-(2R,3S)-1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-diol 99.81% 否
HY-119940 MC180295 Inhibitor 98.89% 否
HY-B1890 (±)-Catechin Inhibitor 99.51% 否
HY-121508 (E/Z)-IT-603 Inhibitor 99.29% 否
HY-160477 DC-SX029 Inhibitor 98.07% 否
HY-120006A (rel)-AR234960 Agonist 98.95% 否
HY-I1030 rel-(1R,2R)-1-(6-Bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol 99.01% 否
HY-160440 rel-VU6021625 Control 99.67% 否
HY-113068 (rel)-β-Tocopherol Inhibitor 98.91% 否
HY-B0757A (±)-α-Tocopherol nicotinate 99.80% 否
HY-482931C rel-(2R,3R)-2-Phenylpiperidin-3-amine dihydrochloride 99.41% 否
HY-W045799 rel-2-(tert-Butoxycarbonyl)octahydrocyclopenta[c]pyrrole-3a-carboxylic acid 97.0% 否
HY-N0683A rel-α-Vitamin E Inhibitor 70.0% 否
HY-70045 (1R,2S,4R)-rel-1-Azabicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 95.0% 否
HY-112163A rel-Zotatifin 97.32% 否
HY-W061724 rel-((1S,2R)-2-(Methoxycarbonyl)cyclopropane-1-carboxylic acid) / 否
HY-114324A rel-PROTAC PARP1 degrader Degrader 98.99% 否
HY-77493 (rel)-Tivantinib Inhibitor 96.45% 否
HY-101387 rel-ACPT-I Agonist 99.0% 否
HY-W073502 rel-(1r,4r)-4-Aminocyclohexane-1-carbonitrile hydrochloride ≥97.0% 否
HY-W547983 rel-Ethyl (2R,3S)-2,3-dimethylcyclopropanecarboxylate 96.69% 否
HY-W710914A rel-HDMP 28 hydrochloride 99.70% 否
HY-128838A (rel)-PROTAC ERRα Degrader-1 98.18% 否
HY-B0176AS rel-Sertraline-d3 hydrochloride Inhibitor / 否
HY-18941B (rel)-Eglumegad Agonist 97.0% 否
HY-N2207 rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan 99.95% 否
HY-RS11823 REL Human Pre-designed siRNA Set A / 否
HY-RS11824 Rel Mouse Pre-designed siRNA Set A / 否
HY-128732 rel-(2R,3S)-2,3-Dihydroxysuccinic acid hydrate 99.96% 否
HY-166238 rel-Linoleic acid-biotin 95.0% 否
HY-78745 rel-(2R,3S,4R,5S)-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid tert-butyl ester / 否
HY-I1031 rel-Bedaquiline 97.56% 否
HY-N2379 rel-(2R,3S)-3-Phenylisoserine methyl ester / 否
HY-W364968 rel-(1S,2R)-2-(((tert-butoxycarbonyl)amino)methyl)cyclopropane-1-carboxylic acid 98.90% 否
HY-111537 rel-AZ5576 Inhibitor / 否
HY-141726S rel-(αR,βR)-β-(2,4-Difluorophenyl)-β-hydroxy-α-methyl-1H-1,2,4-triazole-1-butanoic acid-d3 / 否
HY-141788S rel-4-Nitrobenzyl (2S,4R)-2-(dimethylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate-d6 / 否
HY-100243A Norcisapride / 否
HY-10121D rel-Asenapine hydrochloride / 否
HY-101512D rel-A-395 hydrochloride Inhibitor / 否
HY-103451A rel-(R,R)-THC Antagonist / 否
HY-10406B rel-Talmapimod hydrochloride / 否
HY-105281 rel-(E)-BMY 21950 sodium / 否
HY-106874B rel-Delequamine / 否
HY-106899A (rel)-MK 287 Control / 否
HY-109092A rel-Licogliflozin Inhibitor / 否
HY-110020 rel-O-2050 Antagonist / 否
HY-113239S1 rel-Hydroxycotinine-d3 / 否
HY-113756B rel-Latanoprost acid Agonist / 否
HY-122495 rel-Quinpirole dihydrochloride Agonist / 否
HY-123876 AS2677131 Inhibitor / 否
HY-12422C rel-(2S,3R)-Voruciclib Inhibitor / 否
HY-12422E rel-(2S,3R)-Voruciclib hydrochloride / 否
HY-124874 (rel)-Asperparaline A Antagonist / 否
HY-12650A (rel)-Mirogabalin Inhibitor / 否
HY-128837A (rel)-Nutlin carboxylic acid / 否
HY-13047A rel-S-(+)-Mecamylamine hydrochloride Antagonist / 否
HY-13204S1 rel-Biperiden-d5 Inhibitor / 否
HY-13204S2 rel-Biperiden EP impurity A-d5 Inhibitor / 否
HY-13204S3 rel-Biperiden EP impurity B-d5 Inhibitor / 否
HY-132210 rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane Antagonist / 否
HY-13607A (rel)-BMS-641988 Antagonist / 否
HY-13631Q (1R,9R)-rel-Exatecan / 否
HY-140902 rel-Biotin-PEG3-C3-NH2 / 否
HY-143785S rel-Saxagliptin-15N,d2 hydrochloride / 否
HY-144681A rel-Ceperognastat Inhibitor / 否
HY-14588S (rel)-Lopinavir-d8 Inhibitor / 否
HY-14645B DHMEQ racemate Inhibitor / 否
HY-14879E rel-Avibactam sodium Inhibitor / 否
HY-151216S rel-Paroxetine-d4 hydrochloride / 否
HY-15322A (rel)-PRT062607 Inhibitor / 否
HY-15793A Trans (2,3)-Dihydrotetrabenazine Inhibitor / 否
HY-17423S1 rel-Abacavir-d4 98.3% 否
HY-17447SA Tranylcypromine-d5 hydrochloride Inhibitor / 否
HY-178240 rel-(1S,2R)-Dihydro bupropion Inhibitor / 否
HY-18295A rel-Erteberel Agonist / 否
HY-18617 rel-SB-612111 hydrochloride Inhibitor / 否
HY-18957A rel-Lifirafenib Control / 否
HY-65039A rel-Boc-Hyp-OMe / 否
HY-78746A (3S,4R,5S)-rel-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxylic acid 96.90% 否
HY-B0141S7 rel-Estradiol-13C6 / 否
HY-N10837 rel-3R-Methoxy-4S-furanogermacra-1E,10(15)-dien-6-one / 否
HY-N15739 (rel)-ent-Chromazonarol / 否
HY-N16764 (rel)-Salcolin A / 否
HY-N16800 rel-Medioresinol / 否
HY-N17087 (rel)-3-Hydroxy-p-menth-1-en-6-one / 否
HY-N17765 rel-(7R,8'R,8S)-Forsythialan C / 否
HY-N17783 rel-Sanleng acid / 否
HY-N7534B (rel)-Epipinoresinol / 否
HY-RS06707 IL17REL Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS11825 Rel Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W015597S rel-3a,4,7,7a-Tetrahydro-1H-isoindole-1,3(2H)-dione-d6 99.40% 否
HY-W1049931 rel-5,5'-((2R,5S)-2,5-Dimethylpiperazine-1,4-diyl)diisophthalic acid / 否
HY-W341900 meso-α,β-Di(4-pyridyl) Glycol / 否
HY-W415923 rel-6-Deoxy-6-fluoroglucopyranose / 否
HY-W456312 (1R,2R)-rel-N1,N2-Dimethyl-N1,N2-bis(pyridin-2-ylmethyl)cyclohexane-1,2-diamine / 否
HY-W588220 rel-cis-Pinic acid / 否
HY-W753222 (aS,bS)-rel-Bedaquiline-d6 / 否
HY-W756041 rel-(1S,2S)-Dihydro bupropion-d9 hydrochloride / 否
HY-10285S1 (rel)-Saxagliptin-13C,d2 TFA Inhibitor / 否
HY-114163A rel-ML123 / 否
HY-12772A rel-Hydroxy Itraconazole / 否
HY-134180 rel-Carbovir monophosphate / 否
HY-137372A rel-trans-Ketoconazole / 否
HY-14588A (rel)-Lopinavir / 否
HY-14690B rel-Ecopipam hydrobromide Antagonist / 否
HY-157571S N-6-[rel-(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinamine-Sonidegib-d8 / 否
HY-157856 rel-4(5)-Epdpe methyl ester / 否
HY-157856A (Rac)-rel-4(5)-Epdpe methyl ester / 否
HY-165804 rel-Methyl (8Z,11Z)-13-((2S,3R)-3-pentyloxiran-2-yl)trideca-8,11-dienoate / 否
HY-165976 rel-(9R,10R)-9,10-Dihydroxyhexadecanoic acid / 否
HY-166057 trans-15,16-Epoxy-octadecanoic acid / 否
HY-166062 trans-5,6-Epoxy-9(Z),12(Z)-octadecadienoic acid / 否
HY-19153 Nepaprazole Inhibitor / 否
HY-90001S3 rel-Ritonavir-d6 98.66% 否
HY-B0492S rel-Paroxetine-d4-1 hydrochloride / 否
HY-B0511S1 rel-Biotin-d4 98.04% 否
HY-N3602A rel-Cleroindicin F Inhibitor / 否
HY-W343009 rel-Biotin methyl ester / 否
HY-W585938 rel-(3R,4S,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride / 否
HY-W745349 rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride Inhibitor / 否
HY-W777138 rel-(1S,2R)-Dihydro bupropion-d9 Inhibitor / 否
HY-Z19657 rel-(R,R)-Glycopyrrolate / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens REL NCBI NCBI:5966
Canis familiaris REL NCBI NCBI:474606
Macaca fascicularis REL NCBI NCBI:102116653
Canis lupus familiaris REL NCBI
Mus musculus REL NCBI NCBI:19696
Rattus norvegicus REL NCBI NCBI:305584
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z